New York, USA - December 17, 2024 - "We're excited to be back at AET US 2024, ready for some stimulating conversations about the latest innovations in antibody therapeutics. It's going to be an amazing opportunity, as always, to connect with researchers and industry experts who are pushing the boundaries of recombinant antibody development." A delegate from Creative Biolabs says.
Recent headlines underscore the booming interest in antibody-based therapies, with recombinant antibodies, biosimilars, and scalable production methods taking center stage. Known for accelerating the development of next-generation antibodies, this prestigious event dives into critical topics like mAbs, bsAbs, ADCs, and oncology-relevant topics like neurodegenerative diseases and tumor microenvironments as well.
Creative Biolabs continues to set the bar in antibody research and development, providing a suite of services designed to meet the most demanding project requirements. Among their standout offerings are:
Recombinant Antibodies
Powered by a proprietary Hi-Affi™ technology, Creative Biolabs delivers recombinant antibodies with unmatched purity (over 98%), affinity, and outstanding reproducibility, which, as versatile as they can be, support extensive applications, from diagnostic tools to therapeutic outreach.
* Human/humanized antibodies, chimeric antibodies, sdAbs, model organism antibodies, etc.
High-Throughput Antibody Production
Addressing the growing need for affordable therapeutic options, Creative Biolabs launches AI-driven high-throughput antibody development & production, which optimizes the antibody screening process to efficiently display multiple antibody variants by phage display systems and integrates single B cell technology for antibody analysis, mutually contributing to the efficient identification and validation of promising antibody candidates with satisfactory binding capabilities.
* Single B Cell Antibody Discovery
* Phage Display-Mediated Antibody Discovery
Non-GMP Antibody Production Pipeline
For early-stage research, Creative Biolabs offers non-GMP antibody production—transitioning monoclonal antibodies through the whole product life cycle from concept in early stage development to large-scale non-GMP commercialization, which are tailored for pilot studies and preclinical testing.
* Prokaryotic Antibody
* Eukaryotic Antibody
The Creative Biolabs team will be in position onsite at the AET 2024 event, ready to discuss their varied, customized antibody discovery solutions. Participants can simply express their project needs and explore what Creative Biolabs can do to help bring their ideas to fruition.
"If you're here at AET, welcome to swing by booth 620 and talk to our team," the delegate says. "Whether you're looking for customized solutions for antibody discovery or a reliable supplier of high-quality research-use reagents, we're here to help make all your visions a reality."
Website: https://www.creativebiolabs.net
About
Creative Biolabs dedicates itself to all top-tier solutions to support antibody R&D from start to finish, focusing on delivering quality, speed, and flexibility to meet the unique needs of every project.
Their event arrangement for 2025 includes:
* Scientist Solution Vendor Event - Johns Hopkins - March 13, 2025
* 16th Annual World Bispecific Summit - September, 2025
* 7th Exosome-Based Therapeutic Development Summit - October, 2025
* 16th Annual World ADC San Diego - November, 2025
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creativebiolabs.net
